Get the Stockscreener App
35.56
0.01%
0.13
Zai Lab Limited Adr stock is traded at $35.56, with a volume of 148.44K.
It is up +0.01% in the last 24 hours and up +22.95% over the past month.
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.
See More
Previous Close:
$35.43
Open:
$35.45
24h Volume:
148.44K
Relative Volume:
0.20
Market Cap:
$3.81B
Revenue:
$355.75M
Net Income/Loss:
$-270.85M
P/E Ratio:
-13.17
EPS:
-2.7
Net Cash Flow:
$-218.63M
1W Performance:
+0.12%
1M Performance:
+22.95%
6M Performance:
+72.76%
1Y Performance:
+75.76%
1-Day Range:
$35.01
$35.84
1-Week Range:
$34.32
$37.99
52-Week Range:
$13.48
$37.99
Zai Lab Limited Adr Stock (ZLAB) Company Profile
Name
Zai Lab Limited Adr
Sector
Industry
Phone
862161632588
Address
4560 JINKE ROAD, SHANGHAI
Compare ZLAB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ZLAB
Zai Lab Limited Adr
|
35.53 | 3.81B | 355.75M | -270.85M | -218.63M | -2.70 |
|
VRTX
Vertex Pharmaceuticals Inc
|
501.63 | 130.96B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
683.33 | 75.53B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
579.08 | 35.07B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
242.10 | 31.72B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
250.34 | 26.76B | 3.32B | -860.46M | -1.04B | -8.32 |
Zai Lab Limited Adr Stock (ZLAB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Mar-03-25 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-14-23 | Initiated | Morgan Stanley | Overweight |
| Aug-10-23 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-21-22 | Initiated | Macquarie | Outperform |
| Oct-12-21 | Initiated | Bernstein | Mkt Perform |
| Apr-28-20 | Initiated | Goldman | Buy |
| Apr-15-20 | Initiated | Guggenheim | Buy |
| Jul-12-19 | Initiated | BofA/Merrill | Buy |
| Jul-05-19 | Initiated | Macquarie | Outperform |
| Jan-29-19 | Initiated | Credit Suisse | Outperform |
| Nov-21-18 | Initiated | Jefferies | Buy |
| Jun-21-18 | Resumed | Leerink Partners | Outperform |
| Feb-14-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-16-17 | Initiated | JP Morgan | Neutral |
| Oct-16-17 | Initiated | Leerink Partners | Outperform |
View All
Zai Lab Limited Adr Stock (ZLAB) Latest News
Zai Lab (NASDAQ:ZLAB) Reaches New 12-Month High – Still a Buy? - Defense World
Brokers Set Expectations for Zai Lab FY2025 Earnings - Defense World
Insider Sell: Richard Gaynor Sells 2,500 Shares of Zai Lab Ltd (ZLAB) - GuruFocus.com
Wall Street Analysts Think Zai Lab Limited (ZLAB) Could Surge 64.42%: Read This Before Placing a Bet - Yahoo Finance
Leerink Partnrs Forecasts Zai Lab FY2026 Earnings - Defense World
Zai Lab (NASDAQ:ZLAB) Receives “Neutral” Rating from Bank of America - Defense World
B of A Securities Downgrades Zai Lab LimitedDepositary Receipt () (ZLAB) - MSN
Zai Lab Announces Participation in Investor Conferences in March 2025 - Business Wire
Zai Lab Limited (NASDAQ:ZLAB) Q4 2024 Earnings Call Transcript - Insider Monkey
Here's Why 'Trend' Investors Would Love Betting on Zai Lab Limited (ZLAB) - MSN
Charles River Laboratories International Inc. stock outperforms competitors on strong trading day - MSN
Zai Lab Limited (ZLAB) Surges 9.0%: Is This an Indication of Further Gains? - Nasdaq
Q1 Earnings Forecast for Zai Lab Issued By Leerink Partnrs - Defense World
Financial Snapshot: Analyzing Zai Lab Limited ADR (ZLAB)’s Key Ratio Metrics - The Dwinnex
Watsco Posts Upbeat Results, Joins GeneDx, Intel And Other Big Stocks Moving Higher On Tuesday - Benzinga
With 73% ownership in Zai Lab Limited (NASDAQ:ZLAB), institutional investors have a lot riding on the business - Yahoo Finance
Zai Lab Limited (NASDAQ:ZLAB) Short Interest Up 27.4% in January - Defense World
Sidley Advised Zai Lab on its Offering of ADSs and Issuance of Underlying Shares - Legal Desire News Network
Analysts Set Expectations for Zai Lab FY2024 Earnings - Defense World
Zai Lab (NASDAQ:ZLAB) Stock Rating Upgraded by Cantor Fitzgerald - Defense World
Forge Global Holdings Inc (FRGE)’s stock chart: A technical perspective - US Post News
Perimeter Solutions Inc (PRM)’s stock price in review: A technical analysis - US Post News
Was anything positive for Zai Lab Limited ADR (ZLAB) stock last session? - US Post News
United Natural Foods Inc (UNFI)’s stock performance: a year in review - US Post News
A stock that deserves closer examination: Cybin Inc (CYBN) - US Post News
Market Highlights: Zai Lab Limited ADR (ZLAB) Ends on a Low Note at 26.77 - The Dwinnex
Daily Progress: Concentrix Corp (CNXC) Drop -0.89, Closing at 48.99 - The Dwinnex
Market Watch: Rekor Systems Inc (REKR)’s Noteworthy Gain, Closing at 2.20 - The Dwinnex
Closing Strong: Selective Insurance Group Inc (SIGI) Ends at 83.49, Up 0.87 from Last Close - The Dwinnex
ZLAB (Zai Lab Limited ADR) may reap gains as insiders became active recently - Knox Daily
Zai Lab Limited ADR (ZLAB) looking to reclaim success with recent performance - SETE News
19,502 Shares in Zai Lab Limited (NASDAQ:ZLAB) Purchased by SG Americas Securities LLC - MarketBeat
SG Americas Securities LLC Makes New $511,000 Investment in Zai Lab Limited (NASDAQ:ZLAB) - Defense World
Wall Street Analysts Believe Zai Lab Limited (ZLAB) Could Rally 95.6%: Here's is How to Trade - Yahoo Finance
Zai Lab to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Recent Corporate Updates on February 27, 2025 - Business Wire
FDA gives Zai Lab’s small cell lung cancer therapeutic orphan drug designation - Mugglehead
Cantor Fitzgerald Comments on Zai Lab FY2025 Earnings - Defense World
Zai Lab Receives Orphan Drug Designation from the U.S. FDA for ZL-1310 (DLL3 ADC) for the Treatment of Small Cell Lung Cancer (SCLC) - Yahoo Finance
Here’s Why Analysts Are Bullish on Zai Lab Limited (ZLAB) - Insider Monkey
Zai Lab Limited (NASDAQ:ZLAB) Position Decreased by JPMorgan Chase & Co. - Defense World
Schrodinger Inc (NASDAQ: SDGR) Up 1.66%: This Is What Analysts Are Now Forecasting - Stocks Register
Zai Lab Announces Acceptance of New Drug Application for KarXT for the Treatment of Schizophrenia - Business Wire
Hennion & Walsh Asset Management Inc. Has $4.80 Million Position in Zai Lab Limited (NASDAQ:ZLAB) - MarketBeat
Zai Lab Announces Positive Topline Results for TIVDAK in the China Subpopulation of the Global Phase 3 innovaTV 301 Trial in Patients with Recurrent or Metastatic Cervical Cancer - Business Wire
Sage Therapeutics (SAGE) Moves 35.1% Higher: Will This Strength Last? - Yahoo Finance
Vertex Pharmaceuticals Incorporated and Zai Lab Limited Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan Region and Singapore - Marketscreener.com
Geode Capital Management LLC Boosts Stock Position in Zai Lab Limited (NASDAQ:ZLAB) - Defense World
Vertex and Zai Lab Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan Region and Singapore - Business Wire
Zai Lab Announces Strategic Partnership with MediLink Therapeutics to Develop a Novel LRRC15 Antibody-Drug Conjugate - Business Wire
Zai Lab Secures Debt Facility to Bolster Financial Standing - TipRanks
Rafael Amado Sells 7,583 Shares of Zai Lab Limited (NASDAQ:ZLAB) Stock - MarketBeat
Zai Lab Limited Adr Stock (ZLAB) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.68%
0.28%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):